|
|
English Français |
Sophia Magalona, Johns Hopkins Bloomberg School of Public Health
Shannon Wood, Johns Hopkins Bloomberg School of Public Health
Frederick E. Makumbi, Johns Hopkins Bloomberg School of Public Health
Simon Peter Sebina Kibira, Makerere University School of Public Health
Georges Guiella, Institut Supérieur des Sciences de La Population de L’Université Joseph Ki-Zerbo
Pierre Akilimali, Université de Kinshasa
Funmilola OlaOlorun, University of Ibadan
Jane Cover, PATH
Philip Anglewicz, Johns Hopkins Bloomberg School of Public Health
DMPA-SC, a pre-filled, subcutaneous injectable contraceptive, may increase contraceptive reach and autonomy given its potential for self-injection. Since its rollout in 2014, however, little is known about sub-Saharan African health systems’ response to this new method. To better understand availability over time, we measure change in stock of DMPA-SC in public and private health facilities and compare with stock trends of other modern methods, utilizing cross-sectional data from Performance Monitoring for Action service delivery point (SDP) surveys in Burkina Faso, DRC (Kinshasa and Kongo Central), Nigeria (Kano and Lagos), and Uganda. Trends in DMPA-SC availability were analyzed and compared with those for other modern methods, by facility type. All geographies showed increasing provision of DMPA-SC over time. More public facilities provided DMPA-SC compared to private facilities; levels of DMPA-SC were lower than DMPA-IM, but comparable to implants and IUDs. Stock availability was more consistent in private facilities in Kinshasa and Kongo Central and in public facilities in Burkina Faso, Kano, and Lagos. Results highlight that while DMPA-SC availability has been increasing since its introduction in sub-Saharan Africa, significant gaps in stock exist. Countries should consider alternative distribution models to address these issues.
Keywords: Family planning and contraception, Cross-country comparative analyses